SENS250117P1000
- 0.20
- +0.03+17.65%
Senseonics Newsroom
NYSE American New 52-Week Highs And Lows
IGM Biosciences IGMS -65% Workforce & Pipeline Reduction; Senseonics SENS +76% Preliminary Revenue
Stifel Maintains Senseonics(SENS.US) With Buy Rating, Maintains Target Price $2.5
Stifel Nicolaus Keeps Their Buy Rating on Senseonics Holdings (SENS)
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket
BTIG Maintains Senseonics(SENS.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Centessa Pharmaceuticals (CNTA)
Reported Earlier, Senseonics Reports $22.5M Preliminary 2024 Revenue With $8.4M In Q4, 56% YoY Patient Growth, And Milestone Eversense 365 Launch Success
Senseonics Holdings: Determined Not to Proceed With Special Meeting of Stockholders to Consider Reverse Stock Split
Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting
Senseonics Holdings Sees 4Q Rev $8.3M >SENS
Here's Why Senseonics Holdings, Inc. (NYSE:SENS) Is Among the Best Diabetes Stocks to Buy Under $10
12 Health Care Stocks Moving In Friday's Pre-Market Session
Insider Purchase: President and CEO of $SENS (SENS) Buys 315,000 Shares
Express News | Senseonics Holdings Inc: Remain on-Target to Achieve Annual Growth of About 50% in Patient Installed Base at End of 2024
Senseonics Holdings Remains On-target To Achieve Annual Growth Of ~50% In Patient Installed Base At The End Of 2024 As Compared With 2023; Reiterates FY24 Global Net Revenue Guidance Of ~$22M
Express News | Senseonics Holdings Inc: Reiterated Full-Year 2024 Global Net Revenue Guidance of About $22 Mln
Senseonics Holdings, Inc. Provides Update on Eversense 365 Launch
Senseonics Discloses Plans for Secondary Offering
Senseonics Holdings Expands With Innovative Diabetes Solutions